Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
DUBLIN, Ireland, Feb. 22, 2017 -- Nexvet Biopharma (Nasdaq:NVET) today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, Massachusetts on Monday, March 6th at 1:20PM ET.
Dr. Heffernan will discuss Nexvet’s pivotal-stage clinical programs for chronic pain in cats and dogs, consisting of ranevetmab and frunevetmab; the significant progress made at the Company’s manufacturing facility, BioNua, as well as the Company’s pipeline.
The presentation will be available on the investor section of Nexvet's website at http://ir.nexvet.com following the completion of the event.
About Nexvet (www.nexvet.com)
Nexvet is a veterinary biologic therapeutics company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet’s proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (mAbs) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, conducts clinical development in the United States and Europe and conducts manufacturing in Ireland.
Further information: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 4 [email protected]
